Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex

Journal of Clinical Investigation

Volumn 123, Issue 9, 2013, Pages 3815-3828

  Huang, Ying ^a   Wu, Zhiping ^a,h   Riwanto, Meliana ^b,c   Gao, Shengqiang ^a   Levison, Bruce S ^a   Gu, Xiaodong ^a   Fu, Xiaoming ^a   Wagner, Matthew A ^a   Besler, Christian ^b,c   Gerstenecker, Gary ^d   Zhang, Renliang ^a   Li, Xin Min ^a   DiDonato, Anthony J ^a,e   Gogonea, Valentin ^a,d   Tang, W H Wilson ^a   Smith, Jonathan D ^a   Plow, Edward F ^a   Fox, Paul L ^a   Shih, Diana M ^f   Lusis, Aldons J ^f   Fisher, Edward A ^g   DiDonato, Joseph A ^a   Landmesser, Ulf ^b,c   Hazen, Stanley L ^a   more..

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF ZURICH   (Switzerland)

^d CLEVELAND STATE UNIVERSITY   (United States)

^e JOHN CARROLL UNIVERSITY   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g NEW YORK UNIVERSITY   (United States)

^h ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 CHLOROTYROSINE; APOLIPOPROTEIN A1; ARYLDIALKYLPHOSPHATASE 1; HIGH DENSITY LIPOPROTEIN; METHIONINE; MYELOPEROXIDASE; TYROSINE; ARYLDIALKYLPHOSPHATASE; PEROXIDASE; PON1 PROTEIN, HUMAN; PROTEIN BINDING;

ACUTE CORONARY SYNDROME; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROMA; BINDING AFFINITY; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOPRECIPITATION; IN VIVO STUDY; INFLAMMATION; MASS SPECTROMETRY; NONHUMAN; OXIDATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN STRUCTURE; PROTEOMICS; RAT; SURFACE PLASMON RESONANCE; AMINO ACID SEQUENCE; ANIMAL; ATHEROSCLEROTIC PLAQUE; C57BL MOUSE; CASE CONTROL STUDY; CELL LINE; CHEMISTRY; DEUTERIUM HYDROGEN EXCHANGE; ENZYME STABILITY; ENZYMOLOGY; KNOCKOUT MOUSE; METABOLISM; MOUSE; OXIDATION REDUCTION REACTION; PROTEIN DOMAIN; PROTEIN SECONDARY STRUCTURE;

AMINO ACID SEQUENCE; ANIMALS; ARYLDIALKYLPHOSPHATASE; CASE-CONTROL STUDIES; CELL LINE; DEUTERIUM EXCHANGE MEASUREMENT; ENZYME STABILITY; HUMANS; LIPOPROTEINS, HDL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OXIDATION-REDUCTION; PEROXIDASE; PLAQUE, ATHEROSCLEROTIC; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN STRUCTURE, SECONDARY;

EID: 84883534311     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI67478     Document Type: Article

References (69)

1. Rye KA, Bursill CA, Lambert G, Tabet F, Barter PJ. The metabolism and anti-atherogenic properties of HDL. J Lipid Res. 2009;50(suppl):S195-S200.
2. Degoma EM, Rader DJ. Novel HDL-directed pharmacotherapeutic strategies. Nat Rev Cardiol. 2011;8(5):266-277.
3. Sattler W, Christison J, Stocker R. Cholesterylester hydroperoxide reducing activity associated with isolated high- and low-density lipoproteins. Free Radic Biol Med. 1995;18(3):421-429.
4. VanLenten BJ, et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response - loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest. 1995;96(6):2758-2767.
5. Mineo C, Yuhanna IS, Quon MJ, Shaul PW. High density lipoprotein-induced endothelial nitric-oxide synthase activation is mediated by Akt and MAP kinases. J Biol Chem. 2003;278(11):9142-9149. (Pubitemid 36800395)
6. Undurti A, Huang Y, Lupica JA, Smith JD, DiDonato JA, Hazen SL. Modification of high density lipoprotein by myeloperoxidase generates a pro-inflammatory particle. J Biol Chem. 2009;284(45):30825-30835.
7. Besler C, et al. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J Clin Invest. 2011;121(7):2693-2708.
8. Garner B, Waldeck AR, Witting PK, Rye KA, Stocker P. Oxidation of high density lipoproteins - II. Evidence for direct reduction of lipid hydroperoxides by methionine residues of apolipoproteins AI and AII. J Biol Chem. 1998;273(11):6088-6095. (Pubitemid 28144688)
9. Karlsson H, Leanderson P, Tagesson C, Lindahl M. Lipoproteomics II: Mapping of proteins in high-density lipoprotein using two-dimensional gel electrophoresis and mass spectrometry. Proteomics. 2005;5(5):1431-1445.
10. Rezaee F, Casetta B, Levels JHM, Speijer D, Meijers JCM. Proteomic analysis of high-density lipoprotein. Proteomics. 2006;6(2):721-730. (Pubitemid 43208050)
11. Alwaili K, et al. The HDL proteome in acute coronary syndromes shifts to an inflammatory profile. Biochim Biophys Acta. 2012;1821(3):405-415.
12. Davidson W, Silva R, Chantepie S, Lagor W, Chapman M, Kontush A. Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters: relevance to antioxidative function. Arterioscler Thromb Vasc Biol. 2009;29(6):870-876.
13. Vaisar T, et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest. 2007;117(3):746-756. (Pubitemid 46348533)
14. Shih DM, et al. Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model. J Clin Invest. 1996;97(7):1630-1639. (Pubitemid 26105474)
15. Bhattacharyya T, et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA. 2008;299(11):1265-1276. (Pubitemid 351439073)
16. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett. 1991;286(1-2):152-154.
17. Watson AD, et al. Protective effect of high density lipoprotein associated paraoxonase - inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest. 1995;96(6):2882-2891.
18. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions - A possible peroxidative role for paraoxonase. J Clin Invest. 1998;101(8):1581-1590. (Pubitemid 28198486)
19. Shih DM, et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature. 1998;394(6690):284-287. (Pubitemid 28335041)
20. Tward A, et al. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation. 2002;106(4):484-490. (Pubitemid 34803695)
21. Tang WHW, et al. Diminished antioxidant activity of high-density lipoprotein-associated proteins in systolic heart failure. Circ Heart Fail. 2011;4(1):59-64.
22. Tang WHW, et al. Clinical and genetic association of serum paraoxonase and arylesterase activities with cardiovascular risk. Arterioscler Thromb Vasc Biol. 2012;32(11):516-522.
23. Zheng LM, et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest. 2004;114(4):529-541.
24. Wang Z, et al. Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med. 2007;13(10):1176-1184. (Pubitemid 47530630)
25. Rudolph TK, et al. Myeloperoxidase deficiency preserves vasomotor function in humans. Eur Heart J. 2012;33(13):1625-1634.
26. Abu-Soud HM, Hazen SL. Nitric oxide is a physiological substrate for mammalian peroxidases. J Biol Chem. 2000;275(48):37524-37532. (Pubitemid 32004861)
27. McMillen TS, Heinecke JW, LeBoeuf RC. Expression of human myeloperoxidase by macrophages promotes atherosclerosis in mice. Circulation. 2005;111(21):2798-2804. (Pubitemid 40791552)
28. Brennan ML, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med. 2003;349(17):1595-1604.
29. Hazen SL, Heinecke JW. 3-chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J Clin Invest. 1997;99(9):2075-2081. (Pubitemid 27203762)
30. Sugiyama S, Okada Y, Sukhova GK, Virmani R, Heinecke JW, Libby P. Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol. 2001;158(3):879-891. (Pubitemid 32221781)
31. Brennan ML, et al. A tale of two controversies - defining both the role of peroxidases in nitrotyrosine formation in vivo using eosinophil peroxidase and myeloperoxidase-deficient mice, and the nature of peroxidase-generated reactive nitrogen species. J Biol Chem. 2002;277(20):17415-17427.
32. Sugiyama S, Kugiyama K, Aikawa M, Nakamura S, Ogawa H, Libby P. Hypochlorous acid, a macrophage product, induces endothelial apoptosis and tissue factor expression - involvement of myeloperoxidase-mediated oxidant in plaque erosion and thrombogenesis. Arterioscler Thromb Vasc Biol. 2004;24(7):1309-1314. (Pubitemid 38880026)
33. Zhang RL, Shen ZZ, Nauseef WM, Hazen SL. Defects in leukocyte-mediated initiation of lipid peroxidation in plasma as studied in myeloperoxidase- deficient subjects: systematic identification of multiple endogenous diffusible substrates for myeloperoxidase in plasma. Blood. 2002;99(5):1802-1810. (Pubitemid 34533056)
34. Zhang RL, et al. Myeloperoxidase functions as a major enzymatic catalyst for initiation of lipid peroxidation at sites of inflammation. J Biol Chem. 2002;277(48):46116-46122.
35. Zheng L, et al. Localization of nitration and chlorination sites on apolipoprotein A-I catalyzed by myeloperoxidase in human atheroma and associated oxidative impairment in ABCA1-dependent cholesterol efflux from macrophages. J Biol Chem. 2005;280(1):38-47. (Pubitemid 40164962)
36. Graner M, James RW, Kahri J, Nieminen MS, Syvanne M, Taskinen MR. Association of paraoxonase-1 activity and concentration with angiographic severity and extent of coronary artery disease. J Am Coll Cardiol. 2006;47(12):2429-2435. (Pubitemid 43866362)
37. Wu ZP, et al. Double superhelix model of high density lipoprotein. J Biol Chem. 2009;284(52):36605-36619.
38. Gogonea V, et al. The low resolution structure of nascent high density lipoprotein reconstituted with DMPC with and without cholesterol reveals a mechanism for particle expansion. J Lipid Res. 2013;54(4):966-983.
39. Gogonea V, et al. Congruency between biophysical data from multiple platforms and molecular dynamics simulation of the double-super helix model of nascent high-density lipoprotein. Biochemistry. 2010;49(34):7323-7343.
40. Gu F, et al. Structures of discoidal high density lipoproteins: a combined computational-experimental approach. J Biol Chem. 2010;285(7):4652- 4665.
41. Li L, Li S, Jones MK, Segrest JP. Rotational and hinge dynamics of discoidal high density lipoproteins probed by interchain disulfide bond formation. Biochim Biophys Acta. 2012;1821(3):481-489.
42. Segrest JP, et al. A detailed molecular belt model for apolipoprotein A-I in discoidal high density lipoprotein. J Biol Chem. 1999;274(45):31755-31758.
43. Wu Z, et al. The refined structure of nascent HDL reveals a key functional domain for particle maturation and dysfunction. Nat Struct Mol Biol. 2007;14(9):861-868. (Pubitemid 47373831)
44. Wu ZP, et al. The low resolution structure of ApoA1 in spherical high density lipoprotein revealed by small angle neutron scattering. J Biol Chem. 2011;286(14):12495-12508.
45. Silva RA, et al. Structure of apolipoprotein A-I in spherical high density lipoproteins of different sizes. Proc Natl Acad Sci U S A. 2008;105(34):12176-12181.
46. Church RFR, Weiss MJ. Diazirines. II. Synthesis and properties of small functionalized diazirine molecules. Observations on the reaction of a diaziridine with the iodine-iodide ion system. J Org Chem. 1970;35:2465-2471.
47. Harel M, et al. Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nat Struct Mol Biol. 2004;11(5):412-419. (Pubitemid 38568944)
48. Ben-David M, et al. Catalytic versatility and back-ups in enzyme active sites: the case of serum paraoxonase 1. J Mol Biol. 2012;418(3-4):181-196.
49. Peng DQ, et al. Apolipoprotein A-I tryptophan substitution leads to resistance to myeloperoxidase-mediated loss of function. Arterioscler Thromb Vasc Biol. 2008;28(11):2063-2070.
50. Annema W, et al. Myeloperoxidase and serum amyloid A contribute to impaired in vivo reverse cholesterol transport during the acute phase response but not group IIA secretory phospholipase A(2). J Lipid Res. 2010;51(4):743-754.
51. Shao B, Tang C, Heinecke JW, Oram JF. Oxidation of apolipoprotein A-I by myeloperoxidase impairs the initial interactions with ABCA1 required for signaling and cholesterol export. J Lipid Res. 2010;51(7):1849-1858.
52. Fiedler TJ, Davey CA, Fenna RE. X-ray crystal structure and characterization of halide-binding sites of human myeloperoxidase at 1.8 A resolution. J Biol Chem. 2000;275(16):11964-11971. (Pubitemid 30237768)
53. Shao B, et al. Tyrosine 192 in apolipoprotein A-I is the major site of nitration and chlorination by myeloperoxidase, but only chlorination markedly impairs ABCA1-dependent cholesterol transport. J Biol Chem. 2005;280(7):5983- 5993. (Pubitemid 40280082)
54. Aviram M, et al. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med. 1999;26(7-8):892-904. (Pubitemid 29198362)
55. Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN. Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon. Br J Pharmacol. 1997;122(2):265-268. (Pubitemid 27397197)
56. Rosenblat M, et al. The catalytic histidine dyad of high density lipoprotein-associated serum paraoxonase-1 (PON1) is essential for PON1-mediated inhibition of low density lipoprotein oxidation and stimulation of macrophage cholesterol efflux. J Biol Chem. 2006;281(11):7657-7665. (Pubitemid 43847536)
57. Rosenblat M, Volkova N, Aviram M. Injection of paraoxonase 1 (PON1) to mice stimulates their HDL and macrophage antiatherogenicity. Biofactors. 2011;37(6):462-467.
58. Berrougui H, Loued S, Khalil A. Purified human paraoxonase-1 interacts with plasma membrane lipid rafts and mediates cholesterol efflux from macrophages. Free Radic Biol Med. 2012;52(8):1372-1381.
59. Charles-Schoeman C, et al. Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritis. Ann Rheum Dis. 2012;71(7):1157-1162.
60. Shiflett AM, Bishop JR, Pahwa A, Hajduk SL. Human high density lipoproteins are platforms for the assembly of multi-component innate immune complexes. J Biol Chem. 2005;280(38):32578-32585. (Pubitemid 41368299)
61. Markwell MA, Haas SM, Bieber LL, Tolbert NE. A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal Biochem. 1978;87(1):206-210. (Pubitemid 9050428)
62. Hatch FT. Practical methods for plasma lipoprotein analysis. Adv Lipid Res. 1968;6:1-68.
63. Aharoni A, Gaidukov L, Yagur S, Toker L, Silman I, Tawfik DS. Directed evolution of mammalian paraoxonases PON1 and PON3 for bacterial expression and catalytic specialization. Proc Natl Acad Sci U S A. 2004;101(2):482-487. (Pubitemid 38084662)
64. Matz CE, Jonas A. Micellar complexes of human apolipoprotein A-I with phosphatidylcholines and cholesterol prepared from cholate-lipid dispersions. J Biol Chem. 1982;257(8):4535-4540.
65. Thiele C, Hannah MJ, Fahrenholz F, Huttner WB. Cholesterol binds to synaptophysin and is required for biogenesis of synaptic vesicles. Nat Cell Biol. 2000;2(1):42-49.
66. Olsen JV, Ong S-E, Mann M. Trypsin cleaves exclusively C-terminal to arginine and lysine residues. Mol Cell Proteomics. 2004;3(6):608-614. (Pubitemid 38878520)
67. Peng J, Elias JE, Thoreen CC, Licklider LJ, Gygi SP. Evaluation of multidimensional chromatography coupled with tandem mass spectrometry (LC/LC-MS/MS) for large-scale protein analysis: the yeast proteome. J Proteome Res. 2003;2(1):43-50. (Pubitemid 36207189)
68. Baumgartel K, Tweedie-Cullen RY, Grossmann J, Gehrig P, Livingstone-Zatchej M, Mansuy IM. Changes in the proteome after Neuronal Zif268 overexpression. J Proteome Res. 2009;8(7):3298-3316.
69. Jin LH, Shieh JJ, Grabbe E, Adimoolam S, Durbin D, Jonas A. Surface plasmon resonance biosensor studies of human wild-type and mutant lecithin cholesterol acyltransferase interactions with lipoproteins. Biochemistry. 1999;38(47):15659-15665. (Pubitemid 129503610)